Experts discuss how real-world patient factors shape first-line renal cell carcinoma treatment choices

Dr. Elizabeth Plimack and Dr. Yasser Ged appeared in a recent segment to talk about first-line treatment selection for renal cell carcinoma.

They explained that beyond clinical trial results, real-world patient characteristics such as risk category, comorbid conditions, and disease subtype influence which regimen is chosen.

The discussion highlighted the need to translate trial data into everyday practice and to consider individual patient factors when planning therapy.